Peptide LibraryCJC-1295 dosage in published studies and labels
These are the doses used for CJC-1295 in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
CJC-1295 has been dosed in humans in two published 2006 studies in healthy adults, which gave 30–60 mcg/kg subcutaneously and reported sustained, dose-dependent increases in growth hormone and IGF-1. That is weight-based dosing from small pharmacology studies, not an established therapeutic regimen: the only registered phase 2 trial was terminated, and no product has been approved.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 30–60 mcg/kg subcutaneously (weight-based) |
| Route | Subcutaneous |
| Frequency | Single and repeated dosing studied; the long-acting DAC form was given at multi-day intervals |
| Duration studied | Short pharmacology studies |
| Titration | None reported. Doses were fixed per weight in the published studies. |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Teichman et al., 2006 — healthy adultsClinical trial · Human pharmacology study | Healthy adults | 30 or 60 mcg/kg (doses up to 120 mcg/kg were studied) | Subcutaneous | Single and repeated dosing | Up to 28 days of follow-up | Growth hormone and IGF-1 secretion, safety and tolerability | Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. |
| Continuous GHRH stimulation study, 2006Clinical trial · Human pharmacology study | Healthy adults | Per study protocol | Subcutaneous | — | — | Whether pulsatile GH secretion persists during continuous stimulation | Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. |
| NCT00267527 — phase 2, terminated, no resultsClinical trial · Phase 2 trial, terminated | HIV patients with visceral obesity (n=120 planned) | Not disclosed | Subcutaneous | — | — | Visceral obesity in HIV | NCT00267527 — A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity |
Where sources disagree
- Published human dosing is weight-based (mcg/kg). The fixed 100 mcg or 2 mg doses commonly published elsewhere are not the same thing, and a fixed dose delivers very different exposure across body weights.
- "CJC-1295" is used for two different molecules: the original long-acting form with a Drug Affinity Complex (DAC), which is what the 2006 studies used, and "CJC-1295 no DAC" (also sold as Mod GRF 1-29), which is a different, much shorter-acting peptide. Human dosing data for the DAC form is not evidence for the no-DAC form.
- The only registered clinical trial of CJC-1295 was terminated and posted no results. No product containing it has been approved anywhere.